AZ’s durvalumab awarded breakthrough status in bladder cancer
February 18, 2016Research and Development AstraZeneca, FDA, bladder cancer
AstraZeneca, and its biologics/R&D arm MedImmune, have won FDA Breakthrough Therapy status for their bladder cancer drug durvalumab (MEDI4736), which …
MPS appoints global marketing leader
February 17, 2016Manufacturing and Production
Multi Packaging Solutions International, a global leader in value-added print and packaging solutions for the branded consumer, healthcare and multi-media …
Pfizer pays $784m to settle Protonix overcharge claims
February 17, 2016Research and Development, Sales and Marketing Medicaid, Pfizer, Wyeth, protonix
US drugs giant Pfizer is to pay more than $784 million to settle claims that it overcharged health insurer Medicaid …
FDA gives Roche MS drug breakthrough status
February 17, 2016Research and Development Genentech, MS, Roche
Roche subsidiary Genentech has been awarded US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its drug Ocrevus (ocrelizumab) …
AbbVie becomes Dementia Consortium’s latest pharma partner
February 16, 2016Manufacturing and Production, Research and Development
AbbVie has become the latest pharmaceutical company to join The Dementia Consortium- a £4 million global collaboration aiming to speed …
What would BREXIT mean for pharma?
February 16, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing research and development
It began with a promise to UK voters to end ‘benefit tourism’ and to negotiate more flexibility in the UK’s …
First Enbrel biosimilar launches in UK
February 16, 2016Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis
Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …
Lilly suffers damaging Alimta patent blow
February 15, 2016Manufacturing and Production, Sales and Marketing Actavis, Alimta, Allergan, Eli Lilly, pemetrexed
Eli Lilly says it plans to appeal a UK High Court’s verdict that could imminently open its blockbuster lung cancer …
New 10-minute test will diagnose cancer at home
February 15, 2016Manufacturing and Production, Research and Development, Sales and Marketing Cancer
Scientists have developed a test for cancer that can diagnose the disease at home with the aid of just a …
FEC stats reveal pharma donations to presidential runners
February 12, 2016Sales and Marketing
Stats from the Center for Responsive Politics and the Federal Election Commission (FEC), have revealed the extent of donations from the …
UK patients get early access to Opdivo for kidney cancer
February 12, 2016Medical Communications, Sales and Marketing
Bristol Myers-Squibb’s Opdivo (nivolumab) will be available through the Early Access to Medicines Scheme (EAMS) as a monotherapy to UK …
Amgen’s Kyprolis now available to UK multiple myeloma patients
February 12, 2016Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma
Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …
Biosimilars: Can the US catch up in 2016?
February 12, 2016Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars
What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …
GSK fined millions over deals to delay generic competition
February 12, 2016Medical Communications, Sales and Marketing GSK seroxat
GlaxoSmithKline has been fined £37.6m by the UK Competition & Markets Authority (CMA) for paying two generic drugmakers to delay …
Sandoz buys rights to Pfizer biosimilar
February 12, 2016Medical Communications, Research and Development, Sales and Marketing Pfiizer, Sandoz, biosimilars
Sandoz has announced further expansion to its biosimilars programme with the acquisition of the European rights to Pfizer’s Remicade (infliximab) …
Incyte to stop Jakafi pancreatic, colorectal cancer drug trials
February 11, 2016Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer
Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
ABPI appoints Mike Thompson as new chief executive
February 11, 2016Medical Communications
The Association of the British Pharmaceutical Industry (ABPI) has appointed former GlaxoSmithKline executive Mike Thompson as its new chief executive …
Genomics England enters bioinformatics partnership with Illumina
February 11, 2016Research and Development Genomics england, Illumia
Genomics England has announced a new partnership with US-based sequencing specialist Illumina to develop a platform and knowledge base that …
Alzheimer’s disease market set to double to $10.4 Billion by 2021
February 11, 2016Research and Development, Sales and Marketing Alzheimer's disease
The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion …
EMA accepts Sandoz Neulasta biosimilar for review
February 11, 2016Research and Development Amgen, Neulasta, Novartis, Sandoz
Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
